Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesNeoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaAn Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsA Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell CarcinomaAn Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaAnti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study)
P6153
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaA Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell CarcinomaNeoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaIntralesional Sclerosant for in Transit and Cutaneous Melanoma MetastasesAnti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study)Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaA Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
P859
Q37384982-7DA32C11-AE67-4CD3-BEE2-8F736D1907D0Q42947998-AD361C0D-4253-47D8-82EC-9755736AD4EBQ58932489-0BC90D48-679F-45F0-807E-14A7CE9AABDFQ58932489-8B8A7FD3-D81A-45C5-8191-4639A516A02AQ58932489-D97368E2-8955-4224-9552-F9AE16E3FC15Q58932489-E830B59A-8634-4DB7-B4FB-C3E760196B7CQ59199964-4D60A3EA-EFA6-4026-AD50-0F8AB7D1383BQ59691319-E4F83B4C-128F-4E81-B73D-89D5DF3BCD02Q64681413-79E35321-A8F7-4487-AD87-4406125122D6Q64884885-480F134F-0EEE-48CF-8CDE-3B7F015D2229Q86547304-79262510-4A9B-48DB-893F-C6DA3BC26FEAQ88487117-C9257862-3B7D-4CBE-B142-34534FE9E596
P108
Q61975209-2ED8B16D-B200-4A8C-B2B7-CB7341443B54Q62814719-DB3E14D3-3A60-4420-AF85-2F279ECBF5A3Q63813252-00FF0909-7473-45F0-B28C-73E20896DCC7Q64172199-098BC538-F6C6-49EC-9EEF-6DEB31BCC51EQ64173540-341B8084-C0FA-4ECC-B229-52CB76910AFFQ64187129-90FDF264-D0B0-417B-A9D6-24A8AFD61BF7Q80365023-7028ADF7-E867-4A1F-B6D5-B9D56EF12C8D
P859
description
australische Non-Profit-Organisation
@de
name
Melanoma Institute Australia
@en
type
label
Melanoma Institute Australia
@en
prefLabel
Melanoma Institute Australia
@en
P131
P17
P213
0000 0004 0491 6278
P2427
grid.419690.3